A larger phase I/II study on 45 pediatric patients with r/r CD19-positive ALL undergoing CAR T-cell therapy estimated the rate of grade ≥3 febrile neutropenia at 4.7% of cases, but no severe infection was cited [160]. This evidence concerns the gene CD19 and infection.